Ex vivo expanded autologous hematopoietic stem cells strongly boost immune activity via cost-effective, human-compatible protocol.

Hematopoietic stem cell (HSC) therapy is a critical approach for treating various hematological and immunological disorders. While autologous HSCs offer the advantage of avoiding complications like graft-versus-host disease, current ex vivo expansion protocols often rely on expensive synthetic media and xeno-derived components. This reliance creates significant hurdles for clinical translation and cost-effectiveness. There is a clear need for minimalist, human- and cGMP-compatible expansion methodologies to make these therapies more accessible and safer.

Researchers isolated CD34+ cells from the peripheral blood of healthy donors. These cells were expanded using an in-house methodology comprising autologous plasma supplemented with stem cell factor and interleukin-3. The expanded HSCs were then co-cultured with autologous peripheral blood mononuclear cells (PBMCs) to evaluate their immunogenic potential. Key parameters assessed included cell viability and CD34+ purity, total white blood cell expansion event counts via flow cytometry, and Interferon-gamma (IFN-gamma) secretion via ELISA.

The novel expansion protocol yielded robust results, demonstrating good viable CD34+ purity and a marginal CD71+ percentage. Functional assays revealed that the presence of these expanded HSCs exerted a potent stimulatory effect on the immune environment. The co-culture group, containing expanded HSCs and corresponding donor PBMCs, exhibited a strong increase in total WBC event counts.

These counts reached an average of 3000 events, significantly higher than the control group's counts of <500 or even less. Furthermore, this interaction induced strong immunogenic activity, characterized by high levels of IFN-gamma secretion, whereas control groups showed negligible cytokine production. These findings underscore the expanded HSCs' capacity as a powerful biological stimulant for leukocyte proliferation and immune signaling.